Literature DB >> 28759377

Evidence-based management of adult patients with diffuse glioma - Authors' reply.

Michael Weller1, Martin van den Bent2, Jörg C Tonn3, Roger Stupp4, Matthias Preusser5, Elizabeth Cohen-Jonathan-Moyal6, Roger Henriksson7, Emilie Le Rhun8, Carmen Balana9, Olivier Chinot10, Martin Bendszus11, Jaap C Reijneveld12, Frederic Dhermain13, Pim French14, Christine Marosi5, Colin Watts15, Ingela Oberg16, Geoffrey Pilkington17, Brigitta G Baumert18, Martin J B Taphoorn19, Monika Hegi20, Manfred Westphal21, Guido Reifenberger22, Riccardo Soffietti23, Wolfgang Wick24.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28759377     DOI： 10.1016/S1470-2045(17)30515-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).

Authors:  Carmen Balana; Maria Angeles Vaz; Juan Manuel Sepúlveda; Carlos Mesia; Sonia Del Barco; Estela Pineda; Jose Muñoz-Langa; Anna Estival; Ramón de Las Peñas; Jose Fuster; Regina Gironés; Luis Miguel Navarro; Miguel Gil-Gil; Miriam Alonso; Ana Herrero; Sergio Peralta; Clara Olier; Pedro Perez-Segura; Maria Covela; Maria Martinez-García; Alfonso Berrocal; Oscar Gallego; Raquel Luque; Franciso Javier Perez-Martín; Anna Esteve; Nuria Munne; Marta Domenech; Salvador Villa; Carolina Sanz; Cristina Carrato
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

Review 2.  The association of 6 variants of 8q24 and the risk of glioma: A meta-analysis.

Authors:  Yu Tong; Lv Ye; Shiping Li; Fengyan Zhao; Junjie Ying; Yi Qu; Jinhui Li; Dezhi Mu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.